A Randomized, Double-Blind, Active-Controlled Phase 2 Trial to Evaluate a Novel Selective and Reversible Intravenous and Oral P2Y12 Inhibitor Elinogrel Versus Clopidogrel in Patients Undergoing Nonurgent Percutaneous Coronary Intervention...

The article discusses a study which investigated the tolerability, efficacy, and safety of elinogrel in patients who underwent nonurgent percutaneous coronary intervention (PCI). The patients were given either 600 or 300 milligrams (mg) clopidogrel followed with 75, 80, or 120 mg IV elinogrel daily and then 50, 100, or 150 mg oral elinogrel two times daily. Compared with clopidogrel, oral and intravenous elinogrel did not increase thrombolysis in myocardial infarction minor or major bleeding.